We determined if p16 or HPV status had any significant impact on OS or CSS in the subset of patients with advanced disease as demonstrated by pathologic tumor stage pT ≥ 3 versus ≤ 2 (31 patients in total) and patients with nodal stage pN ≥ 2 versus ≤ 1 (52 patients in total). Here, CDKN2A is linked to neoplasm.